The drug combination trimethoprim/polymyxin (INNs, trade name Polytrim) is an antimicrobial solution for topical ophthalmic use in the treatment of acute bacterial conjunctivitis and blepharoconjunctivitis. == References ==
Sodium zirconium cyclosilicate (ZS-9), sold under the brand name Lokelma, is a medication used to treat high blood potassium. Onset of effects occurs in one to six hours. It is taken by mouth.Common side effects include swelling and low blood potassium. Use is likely safe in pregnancy and breastfeeding. It works by binding potassium ions in the gastrointestinal tract which is then lost in the stool.Sodium zirconium cyclosilicate was approved for medical use in the European Union and in the United States in 2018. It was developed by AstraZeneca. Medical use
Sodium zirconium cyclosilicate is used to treat high blood potassium. Onset of effects occurs in one to six hours.One review found a decrease in potassium of 0.17 mEq/L at one hour and 0.67 mEq/L at 48 hours.It appears effective in people with chronic kidney disease, diabetes, and heart failure. Use has been studied for up to a year. Mechanism of action
ZS-9 is a zirconium silicate. Zirconium silicates have been extensively used in medical and dental applications because of their proven safety. 11 zirconium silicates were screened by an iterative optimization process. ZS-9 selectively captures potassium ions, presumably by mimicking the actions of physiologic potassium channels. ZS-9 is an inorganic cation exchanger crystalline with a high capacity to entrap monovalent cations, specifically potassium and ammonium ions, in the GI tract. ZS-9 is not systemically absorbed; accordingly, the risk of systemic toxicity may be minimized. Background
Hyperkalemia is rare among those who are otherwise healthy. Among those who are in hospital, rates are between 1% and 2.5%.